LIBRARIES AND DATA STRUCTURES OF MATERIALS REMOVED BY DEBULKING CATHETERS

Abstract

Material removed by a debulking catheter from a body lumen can be preserved. Materials can be collected from many different patients and/or from multiple procedures on individual patients. Data which describe the properties or qualities of the removed material and/or the patient and/or the patient's family or environment can be stored on computer readable media. The stored data can be used to draw correlations, to stratify groups of patients, to provide risk assessments, to provide diagnoses and/or prognoses. Further tests can be done on the stored materials at later times after the procedures have been completed.

Description

CROSS-REFERENCES TO RELATED APPLICATION

This application is a continuation and claims the benefit of priority under 35 U.S.C. §120 of U.S. patent application Ser. No. 12/880,010, filed Sep. 10, 2010, which is a continuation of U.S. patent application Ser. No. 11/230,924, filed Sep. 21, 2005, now U.S. Pat. No. 7,794,413 B2, issued Sep. 14, 2010, which is a continuation-in-part of U.S. patent application Ser. No. 11/108,887, filed Apr. 19, 2005, now abandoned, the contents of each of which are hereby incorporated by reference herein.

TECHNICAL FIELD OF THE INVENTION

The present invention relates generally to computer readable media for storing data relating to patients and tissue samples excised from their vascular or other lumens. The data may be used to analyze current, past, or future patient health, to assess treatments, to evaluate drugs, to evaluate risk factors, and to determine proposed treatments or assessments.

BACKGROUND OF THE INVENTION

Cardiovascular disease frequently arises from the accumulation of atheromatous material on the inner walls of vascular lumens, particularly arterial lumens of the coronary and other vasculature, resulting in a condition known as atherosclerosis. Atherosclerosis occurs naturally as a result of aging, but may also be aggravated by factors such as diet, hypertension, heredity, vascular injury, and the like. Atheromatous and other vascular deposits restrict blood flow and can cause ischemia which, in acute cases, can result in myocardial infarction. Atheromatous deposits can have widely varying properties, with some deposits being relatively soft and others being fibrous and/or calcified. In the latter case, the deposits are frequently referred to as plaque.

One conventional treatment for cardiovascular disease is the use of stents. Endoluminal stents are commonly used to treat obstructed or weakened body lumens, such as blood vessels and other vascular lumens. Once deployed in the blood vessel, the stent can remain in the body lumen where it will maintain the patency of the lumen and/or support the walls of the lumen which surround it. One factor impeding the success of stent technology in endoluminal treatments is the frequent occurrence of in-stent restenosis, characterized by proliferation and migration of smooth muscle cells within and/or adjacent to the implanted stent, causing reclosure or blockage of the body lumen.

Atherosclerosis and restenosis can be treated in a variety of ways, including drugs, bypass surgery, and a variety of catheter-based approaches which rely on intravascular debulking or removal of the atheromatous or other material occluding a blood vessel. Of particular interest to the present invention, a variety of methods for cutting or dislodging material and removing such material from the blood vessel have been proposed, generally being referred to as atherectomy procedures. Atherectomy catheters intended to excise material from the blood vessel lumen generally employ a rotatable and/or axially translatable cutting blade which can be advanced into or past the occlusive material in order to cut and separate such material from the blood vessel lumen.

There is a need in the art for methods and tools for managing and storing materials removed from body lumens. There is a need in the art for methods and tools for managing and storing information related to and/or derived from materials removed from body lumens.

BRIEF SUMMARY OF THE INVENTION

One aspect of the invention provides one or more computer readable media having a data structure stored thereon. The data structure comprises a first data field comprising a value corresponding to a property of a first tissue sample excised from a vascular lumen of a patient and a second data field comprising data identifying the patient. Optional additional data fields include a third data field comprising a value corresponding to cardiac health of the patient, a fourth data field comprising a value corresponding to a characteristic of the patient's blood, a fifth data field comprising a value corresponding to family history of the patient, a sixth data field comprising a value corresponding to the patient's medical history, a seventh data field comprising a value corresponding to a property of a second tissue sample excised from a vascular lumen of the patient at a distinct time, an eighth data field comprising a value corresponding to a property of a second tissue sample excised from distinct vascular lumen of the patient on the same day as the first tissue sample, a ninth data field which comprises a value which links a labeled storage container comprising excised tissue with a value in the second data field, a tenth data field which comprises a value which links the labeled storage containers comprising a component extracted or processed from an extracted tissue with a value in the second data field. These can be used separately or cumulatively. These data fields are not an exclusive list of possible useful data fields.

For a further understanding of the nature and advantages of the invention, reference should be made to the following description.

DETAILED DESCRIPTION OF THE INVENTION

Data collected related to samples of materials removed from body lumens can be stored in data structures. The stored data can be used to draw correlations, to stratify groups of patients, to provide risk assessments, to provide diagnoses and/or prognoses. Libraries of samples can be assembled to be used for studies of drugs, candidate drugs, toxins, therapeutic treatments, etc. The samples can be preserved according to any method known in the art. Samples may be frozen, for example, in liquid nitrogen. They may be preserved in paraffin, dried, freeze dried, etc. Samples may be treated to achieve a purified or semi-purified component of the sample. Samples may be treated, for example to extract DNA or protein. Samples may be treated to extract mRNA and to preserve it or “convert” it to cDNA. Desirably, samples are stored in a consistent and systematic way so that patient information remains associated with the samples so that patient outcome or other data collected at a later time can be associated with the sample concurrently or at a later time.

Samples within a library can be stored and associated with information related to the sample itself, e.g., its properties, and the patient from whom the sample was excised. Other information that can be associated with the sample include results of analyses of the sample, patient history information, patient outcome information, drug efficacy information, therapeutic efficacy information, family history, factors of the patient related to cardiac disease, factors of the patient related to non-cardiac disease. In some cases this information may be stored without association with the physical samples. Patient identifying information may be coded so that confidentiality can be maintained while still permitting correlation of various patient attributes with the samples.

One or more aspects of the invention may be embodied in computer-usable data and computer-executable instructions, such as in one or more program modules, executed by one or more computers or other devices. Generally, program modules include routines, programs, objects, components, data structures, etc. that perform particular tasks or implement particular abstract data types when executed by a processor in a computer or other device. The computer executable instructions may be stored on a computer readable medium such as a hard disk, optical disk, removable storage media, solid state memory, RAM, etc. As will be appreciated by one of skill in the art, the functionality of the program modules may be combined or distributed as desired in various catheters. In addition, the functionality may be embodied in whole or in part in firmware or hardware equivalents such as integrated circuits, field programmable gate arrays (FPGA), and the like. Particular data structures may be used to more effectively implement one or more aspects of the invention, and such data structures are contemplated within the scope of computer executable instructions and computer-usable data described herein.

Data fields which are present in the data structures of the present invention may include one or more of those discussed below. A first data field comprises a value corresponding to a property of a first tissue sample excised from a vascular lumen of a patient. The tissue sample is typically material that has been excised from a body lumen. The body lumen is often a vascular lumen. The property may be, for example, level of a marker in the tissue, composition of the tissue sample, histologic characterization, immunochemical characterization of the tissue, a genomic characteristic of the tissue, level of a mRNA in the tissue, location of the vascular lumen from which the tissue was excised, or volume or mass of the excised tissue. Any property of the tissue may be stored in this data field. A second data field may comprise data identifying a patient. The patient data may be anonymous or identify a person. If anonymous, the code will uniquely identify a patient's characteristics, without actually identifying the patient. Thus data can be used for studies, without divulging identities of the patients.

An optional third data field comprises a value corresponding to cardiac health of the patient. Such values may, for example, relate to past infarct history, past angioplasty procedures, or past cholesterol values. A possible fourth data field comprises a value corresponding to a characteristic of the patient's blood. The blood may have been withdrawn at the time of or before tissue excision. The blood characteristic may be any known in the art, including but not limited to, sedimentation rate, red blood cell count, white blood cell count, triglycerides, and C-reactive protein.

An optional fifth data field comprises a value corresponding to family history of the patient. Thus a value can be assigned to family history events based on degree of relatedness of the family member and the severity of the event. An optional sixth data field comprises a value corresponding to the patient's own medical history. This history includes but is not limited to cardiac related events. Thus other medical history events can be recorded which may not be currently known to be associated with vascular occlusion, but which may in fact have a correlation. Such data will make the data structure useful for discovering new associations, risks, and mechanisms. Such data may also be useful in stratifying patients for treatment regimens and for drug trials.

An optional seventh data field comprises a value corresponding to a property of a second tissue sample excised from a vascular lumen of the patient at a distinct time from the first tissue sample. The second tissue sample can be excised from the same vascular lumen as the first tissue sample or from a different vascular lumen of the patient. An optional eighth data field comprises a value corresponding to a property of a second tissue sample excised from a distinct vascular lumen of the patient on the same day as the first tissue sample.

The computer readable media can optionally be associated with one or more excised tissue samples in labeled storage containers. Labeled storage containers includes storage containers that are in fixed positions or parts of a machine or apparatus which positions are themselves labeled. If such stored tissue samples are associated with the data structure, an optional ninth data field can be used which comprises a value which links the labeled storage containers with a value in the second data field. Alternatively, the labeled storage containers may be labeled with a value in the second data field. Alternatively or optionally the data structure can be associated with labeled storage containers in which one or more samples comprise a component extracted or processed from an excised vascular tissue from a vascular lumen of the patient. Such components include DNA, RNA, cDNA, lipid, carbohydrate, and protein. In such a case, the data structure can optionally comprise a tenth data field in which a value which links the labeled storage containers with a value in the second data field is present. Alternatively, such labeled storage containers can be labeled with a value in the second data field. There is no significance to the numbers of the data fields as used herein. Data fields with sequential numbers need not be used. Thus, for example, a structure can comprise data fields with fields 1, 2, 5, and 6 without data fields 3, 4, 7, 8, 9, and 10.

Catheters can be used to debulk atheroma and other occlusive material from diseased body lumens, and in particular coronary arteries, de novo lesions, and in-stent restenosis lesions. Catheters are also suitable for treating stenoses of body lumens and other hyperplastic and neoplastic conditions in other body lumens, such as the ureter, the biliary duct, respiratory passages, the pancreatic duct, the lymphatic duct, and the like. Neoplastic cell growth will often occur as a result of a tumor surrounding and intruding into a body lumen. Debulking of such material can thus be beneficial to maintain patency of the body lumen. The debulked material is typically a continuous strip of tissue removed from the lumen interior wall that ranges from about 1 mg to about 2000 mg; it retains the structure of the tissue prior to removal. The continuous strip or strand of tissue removed will typically have a length that is longer than a length of the cutting window. The data storage and access structures of the present invention can be applied to a variety of occlusive, stenotic, or hyperplastic material in a variety of body lumens.

Apparati will generally comprise catheters having catheter bodies adapted for intraluminal introduction to the target body lumen. The dimensions and other physical characteristics of the catheter bodies will vary significantly depending on the body lumen which is to be accessed. In the exemplary case of atherectomy catheters intended for intravascular introduction, the proximal portions of the catheter bodies will typically be very flexible and suitable for introduction over a guidewire to a target site within the vasculature.

Generally, the smooth muscle cells of the stenotic material show a range of phenotypes, but most of the cells contained myofilaments as well as a relatively high amount of synthetic organelles, such as rough endoplasmic reticulum, Golgi apparatus and mitochondria. One can determine how much stenotic tissue is retrieved in an access procedure. One can determine presence or absence of inflammatory cells in excised tissue. One can determine the presence of inflammatory cells within critical areas of plaque. Determination of the location and degree of inflammatory cells present may facilitate a more informed characterization or diagnosis.

The material removed from a catheter collection chamber, or a portion thereof, can be placed in a preserving agent, a tissue fixative, and or a preparation agent suitable for a desired test prior to testing the material. The material removed from the patient by this method is typically at least one or more continuous strip(s) of material that maintains the structure of the material in vivo. The quantity of material removed by the method can be from about 1 mg to about 2000 mg. Typically the amount of material is about 1 mg to about 100 mg, about 100 mg to about 200 mg, about 200 mg to about 300 mg, 300 mg to about 400 mg, 400 mg to about 500 mg, 500 mg to about 600 mg, about 600 mg to about 700 mg, 700 mg to about 800 mg, or about 800 mg to about 2000 mg. In a typical procedure about 400 mg to about 600 mg of material is removed and available for testing and/or storage. Collection of one or more continuous strips of material from the inner surface of a lumen may be longer than a largest dimension of the cutting window of a catheter used to remove the material. In a particular example, the material can comprise plaque tissue. The material can be collected from a single site or at least one additional site in the same or a different body lumen.

Excised material can be stored to permit later confirmatory or additional testing without having to subject the patient to another percutaneous translumenal lumenectomy procedure. The material can be tested by genomic screening, DNA hybridization, RNA hybridization, gene expression analysis, PCR amplification, proteomic testing, drug efficacy screening, presence of one or more protein markers, presence of one or more DNA markers, presence of one or more RNA markers, histological testing, histopathology, cytopathology, cell and tissue type analysis, biopsy, and the like. Additionally, the material can also be cultured and/or tested to determine sensitivity to drugs, toxins, and the like. The material can be tested for the presence of DNA, RNA, or protein markers comprising a smooth muscle proliferative promoter, a smooth muscle proliferative inhibitor, a cellular marker, an apoptotic marker, a cell cycle protein, a transcriptional factor, a proliferative marker, an endothelial growth factor, an adhesion molecule, a cytokine, a chemokine, a chemokine receptor, an inflammation marker, a coagulation factor, a fibrinolytic factor, an oxidative stress related molecule, an extracellular matrix molecule, an interleukin, a growth factor, a glycoprotein, a proteoglycan, a cell-surface marker, a serum marker, and or an immune factor, and the like. Tests for each of these molecules and others are well known to the skilled artisan as are methods and preservatives, fixatives and preparation agents for adding to all or a portion of the material collected. The results of any of the tests for properties of the removed material can be stored in a data structure according to the invention.

The material produced by a lumenectomy comprises at least one continuous tissue stand collected in vivo from an inner surface of the body lumen of a subject. The body lumen can be an artery or other lumen or vessel of the circulatory system and the material can comprise arterial plaque and associated tissue. The continuous strand of tissue provided by the disclosed methods provide a sufficient amount of high quality material to successfully perform at least one or more tests comprising, for example, genomic screening, DNA hybridization, RNA hybridization, gene expression analysis (including serial analysis of gene expression), PCR amplification, proteomic testing, drug efficacy screening, a determination of the presence of one or more protein markers, a determination of the presence of one or more DNA markers, a determination of the presence of one or more RNA markers, histological testing, histopathology, cytopathology, cell type analysis, tissue type analysis, biopsy, and the like. Methods for performing each of the tests are well known to the skilled artisan. It is also well known that material collected from a patient can be added to a preserving agent, tissue fixative, or a preparation agent in order to prepare at least a portion of collected material for the desired test. Agents known in the art for preserving, fixing or preparing the material for later use include, for example, saline, heparinized saline, liquid nitrogen, formalin, a membrane lysis agent, a RNA or DNA preparation agent, and the like. Particular tests that can be carried out successfully on the excised lumenectomy material include, but are not limited to, histology techniques including hematoxylin and eosin staining, connective tissue staining, carbohydrate staining, and lipid staining, and the like. In addition, tissue array testing, enzyme histochemistry, transmission electron microscopy, immunohistology, immunocytochemistry, immunoassays, immunofluorescent assays, immunoprecipitation assays, ELISA, flow cytometry, fluorescent activated cell sorting, radioimmunochemistry, electrophoresis, two-dimensional gel electrophoresis, Western blotting, protein sequencing, mass spectrometry, proteomic analysis, and protein microarray analysis can be carried out. Further, cytogenetic testing, Nothern blotting, RNase protection assays, in situ hybridization assays, DNA microarray testing, reverse transcription polymerase chain reaction PCR (RT-PCR), Southern blotting, DNA sequencing, PCR amplification, single strand conformational polymorphism assays, single strand polymorphism (SNP) assays, and serial analysis of gene expression (SAGE) assays can be successfully carried out with the lumenectomy materials compositions. The compositions can also be prepared for storage for later testing.

Table 1 shows relevant markers for which the excised vascular material can be tested for expression, and about which data can be stored.

TABLE 1
Markers upregulated in vascular disease
AA775616   osteopontin
AA682386   oxidised low density lipoprotein (lectin-like) receptor 1
AA969504   interferon, gamma
AA102526   interleukin 8
BU631490   tissue inhibitor of metalloproteinase 2
NM 002356  myristoylated alanine-rich protein kinase C substrate
NM 000930  plasminogen activator, tissue
NM 002117  major histocompatibility complex, class I, C
AI129421   interleukin 18 (interferon-gamma-inducing factor)
W51794     matrix metalloproteinase 3 (stromelysin 1, progelatinase)
AA143201   matrix metalloproteinase 1 (interstitial collagenase)
N94616     laminin, alpha 4
NM 021999  integral membrane protein 2B
NM 000584  interleukin 8
NM 002510  glycoprotein (transmembrane) nmb
N53447     integral membrane protein 2A
NM_002659  plasminogen activator, urokinase receptor
AL133111   SII3-domain binding protein 5 (BTK-associated)
NM_147780  cathepsin B
W46577     endothelial cell-specific molecule 1
AA857496   matrix metalloproteinase 10 (stromelysin 2)
NM_005502  ATP-binding cassette, sub-family A (ABC1), member 1
AI342012   macrophage scavenger receptor 1
AA490846   integrin, alpha 4 (antigen CD49D, alpha 4 subunit of VLA-4
           receptor)
AA454999   hypothetical protein FLJ10111
AK093984   hypothetical protein MGC5618
AA666269   integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61)
NM_005625  syndecan binding protein (syntenin)
BC014989   phospholipid scramblase 3
AI279830   protein phosphatase 1, regulatory (inhibitor) subunit 16B
AA936768   interleukin 1, alpha
NM_ 001920 decorin
AK055130   calmodulin 2 (phosphorylase kinase, delta)
NM_016497  mitochondrial ribosomal protein L51
AA451863   CD4 antigen (p55)
NM_058197  cyclin-dependent kinase inhibitor 2A
R10284     hyaluronan-mediated motility receptor (RHAMM)
AI309439   integrin, alpha M (complement component receptor 3, alpha)
AI334914   integrin, alpha 2b
AF001893   multiple endocrine neoplasia I
N36136     endomucin-2
AW772163   hypothetical protein FLJ20401
NM_001964  early growth response 1
AA454668   prostaglandin-endoperoxide synthase 1
NM 004530  matrix metalloproteinase 2
AK027663   stanniocalcin 2
AA057204   interleukin 2 receptor, beta
NM_001444  Fatty acid binding protein 5 (psoriasis-associated)
AA873792   small inducible cytokine A5 (RANTES)
Markers upregulated in diabetes
AA936768   interleukin 1, alpha
NM_000600  interleukin 6 (interferon, beta 2)
N98591     interleukin 6 (interferon, beta 2)
AA156031   metallothionein 2A
NM_001235  serine (or cysteine) proteinase inhibitor, Glade H
BF131637   metallothionein 2A
NM_006216  serine (or cysteine) proteinase inhibitor, Glade E
NM_001552  insulin-like growth factor binding protein 4
NM_004530  matrix metalloproteinase 2
NM_000088  collagen, type I, alpha 1
NM_023009  MARCKS-like protein
NM_003670  basic helix-loop-helix domain containing, class B, 2
T8095      Hs. clone 24707 mRNA sequence
NM_002993  chemokine C-X-C motif, granulocyte chemotactic protein 2
NM_006756  transcription elongation factor A (SII), 1
AI983239   Hs. cDNA FLJ32163 fis, clone PLACE6000371
NM_005110  glutamine-fructose-6-phosphate transaminase 2
NM_000584  interleukin 8
AK092836   Homo sapiens cDNA FLJ35517 fis, clone SPLEN2000698
NM_000104  cytochrome P450, subfamily I (dioxin-inducible), peptide
NM_004966  heterogeneous nuclear ribonucleoprotein F
AK025599   mannosidase, alpha, class 1A, member 1
NM_002923  regulator of G-protein signalling 2, 24kDa
AW005755   macrophage migration inhibitory factor
AA873792   small inducible cytokine AS (RANTES)
U72621     pleiomorphic adenoma gene-like 1
NM_000358  transforming growth factor, beta-induced, 68kDa
AK054688   Homo sapiens cDNA FLJ30126 fis, clone BRACE1000114
BC007583   Homo sapiens, clone MGC: 15572 IMAGE: 3140342
NM_000089  collagen, type I, alpha 2
NM_004404  neural precursor cell expressed, developmental regulated 5
NM_078467  cyclin-dependent kinase inhibitor 1A (p21, Cip1)
U97105     Homo sapiens N2A3 mRNA, complete cds
AI356451   CD19 antigen
BF732465   tissue inhibitor of metalloproteinase 2
NM_001554  cysteine-rich, angiogenic inducer, 61
BQ890604   Homo sapiens URB mRNA, complete cds
NM_002631  phosphogluconate dehydrogenase
N94503     pregnancy-associated plasma protein A
NM_001710  B-factor, properdin
Markers upregulated in normal (non0diabetic)
vessel segments
NM_000584  interleukin 8
N98591     interleukin 6 (interferon, beta 2)
AA936768   interleukin 1, alpha
BM803108   ESTs
NM_000600  interleukin 6 (interferon, beta 2)
AI359876   EST
AA156031   metallothionein 2A
BF131637   metallothionein 2A
NM_003670  basic helix-loop-helix domain, class B, 2
NM_001235  serine (or cysteine) proteinase inhibitor, Glade H
NM_004530  matrix metalloproteinase 2
NM_002982  monocyte chemotactic protein 1
NM_002631  phosphogluconate dehydrogenase
NM_078467  cyclin-dependent kinase inhibitor 1 A (p21, Cipl)
NM_152862  actin related protein 2/3 complex, subunit 2
NM_002923  regulator of G-protein signalling 2, 24kDa
A1983239   Hs. cDNA FLJ32163 fis, clone PLACE6000371
NM_005415  solute carrier family 20, member 1
AW772163   hypothetical protein FLJ20401
R21535     Hs. cDNA FLJ11724 fis, clone HEMBA1005331
NM_005110  glutamine-fructose-6-phosphate transaminase 2
AK092836   cDNA FLJ35517 fis, clone SPLEN2000698
NM_006216  serine (or cysteine) proteinase inhibitor, clade E
Markers which are downregulated with statin treatment
NM 000600  interleukin 6 (interferon, beta 2)
N98591     interleukin 6 (interferon, beta 2)
NM_005746  pre-B-cell colony-enhancing factor
NM_ 002852 pentaxin-related gene, rapidly induced by IL-1 beta
N9201      fatty acid binding protein 4, adipocyte
NM_005110  glutamine-fructose-6-phosphate transaminase 2
AK094728   cDNA FLJ37409 fis, similar to COMPLEMENT C3
NM_004000  chitinase 3-like 2
NM_002923  regulator of G-protein signalling 2, 24kDa
T80495     Hs. clone 24707 mRNA sequence
AA936768   interleukin 1, alpha
NM_145791  microsomal glutathione-S-transferase 1
NM_006169  nicotinamide N-methyltransferase
AW007736   UDP-glucose ceramide glucosyltransferase
NM_005420  sulfotransferase, estrogen-preferring
NM_003670  basic helix-loop-helix domain containing, class B, 2
AA425102   monocyte chemotactic protein 1
NM_003254  tissue inhibitor of metalloproteinase 1
BF131637   metallothionein 2A
NM_000104  cytochrome P450, subfamily I (dioxin-inducible)
NM_001733  complement component 1, r subcomponent
NM_032849  hypothetical protein FLJ14834
NM_005328  hyaluronan synthase 2
NM_002009  fibroblast growth factor 7 (keratinocyte growth factor)
NM_002615  serine (or cysteine) proteinase inhibitor, Glade F
NM_002658  plasminogen activator, urokinase
NM_033439  DVS27-related protein
AA381343   interleukin 6 (interferon, beta 2)
AW780123   ribosomal protein S26
M14219     chondroitin/dermatan sulfate proteoglycan (PG40) core
AF495759   Homo sapiens unknown mRNA
NM_001679  ATPase, Na+/K+ transporting, beta 3 polypeptide
NM_001029  ribosomal protein S26
NM_002074  guanine nucleotide binding protein, beta polypeptide 1
NM_001552  insulin-like growth factor binding protein 4
AF208043   interferon, gamma-inducible protein 16
AI268937   monocyte chemotactic protein 2
AA040170   monocyte chemotactic protein 3
AW131311   EST
NM_005415  solute carrier family 20 (phosphate transporter), member 1
NM_006988  a disintegrin-like and metalloprotease (reprolysin type)
NM_006307  sushi-repeat-containing protein, X chromosome
NM_000584  interleukin 8
D31887     KIAA0062 protein
NM_002229  jun B proto-oncogene
NM_002982  monocyte chemotactic protein 1
Markers downregulated with statin treatment
NM_002615  serine (or cysteine) proteinase inhibitor, Glade F
AK094728   Homo sapiens cDNA FLJ37409 fis, clone BRAMY2028516
NM_001552  insulin-like growth factor binding protein 4
N92901     fatty acid binding protein 4, adipocyte
N98591     interleukin 6 (interferon, beta 2)
NM_000104  cytochrome P450, subfamily I (dioxin-inducible)
NM_006756  transcription elongation factor A (SII), 1
NM_000600  interleukin 6 (interferon, beta 2)
AF506819   Homo sapiens URB mRNA, complete cds
NM_145791  microsomal glutathione S-transferase 1
N39161     CD36 antigen (thrombospondin receptor)
M14219     Human chondroitin sulfate proteoglycan core protein
NM_031476  hypothetical protein DKFZp434B044
NM_000186  H factor 1 (complement)
NM_003254  tissue inhibitor of metalloproteinase 1
N98-391    interleukin 6 (interferon, beta 2)
AJ318805   ESTs, Weakly similar to hypothetical protein FLJ20378
AA284954   colony stimulating factor 1 receptor
NM_002923  regulator of G-protein signalling 2, 24kDa
NM_001920  decorin
B160199    likely ortholog of mouse Urb
AA451863   CD4 antigen (p55)
AA464526   interleukin 1 receptor, type I
AW192258   sprouty homolog 4 (Drosophila)
N68859     intercellular adhesion molecule 1 (CD54)
BC007552   Homo sapiens, clone MGC: 15473 IMAGE: 2967168, mRNA
NM_001733  complement component 1, r subcomponent
NM_006288  Thy-1 cell surface antigen
NM_000201  intercellular adhesion molecule 1 (CD54)
R22412     platelet/endothelial cell adhesion molecule (CD31 antigen)
NM_013417  isoleucine-tRNA synthetase
NM_004000  chitinase 3-like 2
R70506     growth factor receptor-bound protein 2
NM_030781  collectin sub-family member 12
NM_001710  B-factor, properdin
NM_006216  serine (or cysteine) proteinase inhibitor, Glade E
NM_005110  glutamine-fructose-6-phosphate transaminase 2
AF506819   Homo sapiens URB mRNA, complete cds
NM_002074  guanine nucleotide binding protein, beta polypeptide 1
H26022     fractalkine, inducible cytokine subfamily D (Cys-X3-Cys)
AK092836   Homo sapiens cDNA FLJ35517 fis, clone SPLEN2000698
BQ890604   Homo sapiens URB mRNA, complete cds
AA057204   interleukin 2 receptor, beta
AI524093   myosin, heavy polypeptide 11, smooth muscle
AI655374   stromal cell-derived factor 1

The material collected can be analyzed for the presence of DNA, RNA, or protein markers comprising smooth muscle proliferative promoters (platelet-derived growth factor (PDGF), and PDGF receptor), basic fibroblast growth factor (FGF) and FGF receptor, interleukin 1 (IL-1), or transforming growth factor α (TGFα), and the like), smooth muscle proliferative inhibitors (nitric oxide/endothelial-derived relaxing factors (NO/EDRF), interferon γ (IFγ), transforming growth factor β (TGFβ), or TGFβ receptor, and the like), cellular markers (including CD68, CD3, CD4, CD8, CD20, smooth muscle actin, or CD31, and the like), apoptotic markers (Bcl-x, Bcl-2, Bax, Bak, or P53, and the like), cell cycle proteins (cyclin A, cyclin B, cyclin D, or cyclin E, and the like), transcriptional factors (transcription factor NFκB, transcription factor E2F, transcription factor CREB, or transcription factor KLF5/BTEB2, and the like), proliferative markers (Ki-67 or proliferating cell nuclear antigen (PCNA), and the like), endothelial growth factors (vascular endothelial growth factor (VEGF), and the like), adhesion molecules (intercellular adhesion molecule-1 (ICAM-1), CD11a/CD18 (LFA-1), CD11b/CD18 (MAC-1), vascular cell adhesion molecule-1 (VCAM-1), p-selectin (CD62P), or integrin, and the like), cytokines (interleukin 6 (IL-6) or interleukin 8 (IL-8), and the like), chemokines and chemokine receptors (monocyte chemoattractant protein 1 (MCP-1) and its receptor CCR2, CX3C chemokine fractalkine and its receptor CX3CR1, or eotaxin and its receptor CCR3, and the like), inflammation markers (C-reactive protein, myeloperoxidase, or complement proteins, and the like), coagulation factors and fibrinolytic factors (fibrinogen, prothrombinogen, plasminogen activator, tissue factor, or glycoprotein receptor on platelets (GpIIb-IIIa), and the like), oxidative stress related molecules (oxidized LDL and its receptor CD36, or lipoxygenase, and the like), extracellular matrix molecules (collagen, matrix metalloproteinase (MMP), FK506-binding protein 12 (FKBP12), endothelial differentiation gene receptors (EDG receptors), ephrins, elastin, lamin receptor, monocyte colony stimulating factor (M-CSF), tumor necrosis factor (TNF), or PDZ domain proteins, and the like), interleukins (interleukin 1 (IL-1), interleukin 6 (IL-6), or interleukin 8 (IL-8), and the like), growth factors (platelet-derived frowth factor (PDGF), basic fibroblast growth factor (FGF), transforming growth factor α (TGFα), or transforming growth factor β(TGFβ), and the like), glycoproteins, proteoglycans (versican, hyluronan, biglycan, or deorin, and the like), cell-surface markers, serum markers, and/or immune factors (stromal cell-derived factor 1a (SDP-1)), and the like). Analysis of the excised material by any of the above tests can be used for diagnosis of a condition in a patient, to design a treatment directive or protocol for a subject, to monitor progress of a treatment regimen, or if tests from a number of individuals are compared, the information can be used in a multi-patient analysis, such as a cardiovascular disease population study.

While all the above is a complete description of the preferred embodiments of the inventions, various alternatives, modifications, and equivalents may be used. Therefore, although the foregoing invention has been described in detail for purposes of clarity of understanding, it will be obvious that certain modifications may be practiced within the scope of the appended claims.

Claims

1. An article of manufacture, said article comprising:

a computer readable media having computer executable instructions stored thereon, which when executed by a computer causes the computer to perform an operation comprising:

receiving a set of data fields derived from a patient sample, wherein the set of data fields comprise: a first value corresponding to a property of a first tissue sample comprising tissue excised from an inner surface of a vascular lumen of a patient, and a second value corresponding to data identifying the patient;

storing the set of data fields;

correlating the first and second values; and

diagnosing the patient.

2. The computer readable media of claim 1 further comprising: a third data field comprising a value corresponding to cardiac health of the patient.

3. The computer readable media of claim 1 wherein the property is a level of a marker in the tissue.

4. The computer readable media of claim 1 wherein the property is composition of the tissue sample.

5. The computer readable media of claim 1 wherein the property is histologic characterization of the tissue.

6. The computer readable media of claim 1 wherein the property is an immunochemical characterization of the tissue.

7. The computer readable media of claim 1 wherein the property is a genomic characteristic.

8. The computer readable media of claim 1 wherein the property is level of a mRNA.

9. The computer readable media of claim 1 wherein the property is location of the vascular lumen from which the tissue was excised.

10. The computer readable media of claim 1 wherein the property is volume or mass of the excised tissue.

11. The computer readable media of claim 1 further comprising: a fourth data field comprising a value corresponding to a characteristic of the patient's blood.

12. The computer readable media of claim 11 wherein the patient's blood was withdrawn at the time of or before tissue excision.

13. The computer readable media of claim 1 further comprising: a fifth data field comprising a value corresponding to family history of the patient.

14. The computer readable media of claim 1 further comprising: a sixth data field comprising a value corresponding to the patient's medical history.

15. The computer readable media of claim 1 further comprising: a seventh data field comprising a value corresponding to a property of a second tissue sample excised from a vascular lumen of the patient at a distinct time.

16. The computer readable media of claim 15 wherein the second tissue sample is excised from the same vascular lumen as the first tissue sample.

17. The computer readable media of claim 1 further comprising: an eighth data field comprising a value corresponding to a property of a second tissue sample excised from distinct vascular lumen of the patient on the same day as the first tissue sample.

18. The computer readable media of claim 1 wherein said media are associated with one or more excised tissue samples in labeled storage containers, wherein the computer readable media comprise a ninth data field which comprises a value which links the labeled storage containers with a value in the second data field.

19. The computer readable media of claim 1 wherein said media are associated with one or more excised tissue samples in labeled storage containers, wherein the storage containers are labeled with a value in the second data field.

20. The computer readable media of claim 1 wherein said media are associated with one or more samples in labeled storage containers, wherein the one or more samples comprise a component extracted or processed from an excised vascular tissue from a vascular lumen of the patient, wherein the component is selected from the group consisting of DNA, RNA, cDNA, and protein, and wherein the computer readable media comprise a tenth data field which comprises a value which links the labeled storage containers with a value in the second data field.

21. The computer readable media of claim 1 wherein said media are associated with one or more samples in labeled storage containers, wherein the storage containers are labeled with a value in the second data field, wherein the samples comprise a component extracted or processed from an excised vascular tissue from a vascular lumen of the patient, wherein the component is selected from the group consisting of DNA, RNA, cDNA, and protein.